AB Science S.A. (AB.PA)
| Previous Close | 0.7750 |
| Open | 0.7730 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7700 - 0.7950 |
| 52 Week Range | 0.7700 - 4.4650 |
| Volume | |
| Avg. Volume | 36,138 |
| Market Cap | 51.618M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | Oct 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY ADDING ONE MORE INDICATION WITH LONG TERM PROTECTION MASITINIB IS IN PHASE 2 IN SICKLE CELL DISEASE Paris, October 28, 2024, 5.45pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to m
- GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024, 7.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following a vote adopted during the Committee for Med
